Avalo Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Avalo Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Avalo Therapeutics Inc AVTX.OQ reported a quarterly adjusted loss of 83 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.92. The mean expectation of twelve analysts for the quarter was for a loss of 58 cents per share. Wall Street expected results to range from -94 cents to -39 cents per share.
Reported revenue was zero; analysts expected zero.
Avalo Therapeutics Inc's reported EPS for the quarter was a loss of 83 cents.
The company reported a quarterly loss of $36.36 million.
Avalo Therapeutics Inc shares had risen by 1.9% this quarter and gained 3.7% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 32.8% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 15 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Avalo Therapeutics Inc is $43.50, about 56.7% above its last closing price of $18.84
This summary was machine generated from LSEG data August 6 at 03:05 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.58 | -0.83 | Missed |
Mar. 31 2026 | -1.03 | -0.98 | Beat |
Dec. 31 2025 | -1.46 | -1.13 | Beat |
Sep. 30 2025 | -1.66 | -2.19 | Missed |